APO Research
Talk to an analyst

APO RESEARCH · REPORT

Female Infertility Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Female Infertility Drugs Market Outlook and Growth Opportunities 2026

22 December 2025199 pages

Choose your research edition.

Industry ResearchFemale Infertility Drugs Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Female Infertility Drugs Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Female Infertility Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Female Infertility Drugs Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Female Infertility Drugs Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Female Infertility Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Female Infertility Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Female Infertility Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Female Infertility Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Female Infertility Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Female Infertility Drugs market include Allergan Plc, Ferring BV, Merck KGaA, Novartis AG and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Female Infertility Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Female Infertility Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Female Infertility Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Female Infertility Drugs market.

Female Infertility Drugs Segment by Company

Allergan Plc

Ferring BV

Merck KGaA

Novartis AG

Sanofi

Female Infertility Drugs Segment by Type

Parenteral

Oral

Others

Female Infertility Drugs Segment by Application

Low Birth Weight

Multiple-gestation Pregnancies

Multiple-birth Infants

Ovarian Hyperstimulation Syndrome

Risk of Cesarean Delivery

Premature Labor

Female Infertility Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Female Infertility Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Female Infertility Drugs key companies, revenue, market share, and recent developments.

3. To split the Female Infertility Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Female Infertility Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Female Infertility Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Female Infertility Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Female Infertility Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Female Infertility Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Female Infertility Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Female Infertility Drugs industry.

Chapter 3: Detailed analysis of Female Infertility Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Female Infertility Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Female Infertility Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Female Infertility Drugs Industry Trends Table 2. Female Infertility Drugs Industry Drivers Table 3. Female Infertility Drugs Industry Opportunities and Challenges Table 4. Female Infertility Drugs Industry Restraints Table 5. Global Female Infertility Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Female Infertility Drugs Revenue Share by Company (2021-2026) Table 7. Global Female Infertility Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Female Infertility Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Female Infertility Drugs Company, Product Type & Application Table 10. Global Female Infertility Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Female Infertility Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Parenteral Table 15. Significant Companies of Oral Table 16. Significant Companies of Others Table 17. Global Female Infertility Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Female Infertility Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Female Infertility Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Female Infertility Drugs Sales Value Share by Type (2021-2026) Table 21. Global Female Infertility Drugs Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Low Birth Weight Table 23. Significant Companies of Multiple-gestation Pregnancies Table 24. Significant Companies of Multiple-birth Infants Table 25. Significant Companies of Ovarian Hyperstimulation Syndrome Table 26. Significant Companies of Risk of Cesarean Delivery Table 27. Significant Companies of Premature Labor Table 28. Global Female Infertility Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Female Infertility Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global Female Infertility Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global Female Infertility Drugs Sales Value Share by Application (2021-2026) Table 32. Global Female Infertility Drugs Sales Value Share by Application (2027-2032) Table 33. Global Female Infertility Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Female Infertility Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global Female Infertility Drugs Sales Value Share by Region (2021-2026) Table 36. Global Female Infertility Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global Female Infertility Drugs Sales Value Share by Region (2027-2032) Table 38. Global Female Infertility Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Female Infertility Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global Female Infertility Drugs Sales Value Market Share by Country (2021-2026) Table 41. Global Female Infertility Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global Female Infertility Drugs Sales Value Market Share by Country (2027-2032) Table 43. Allergan Plc Company Information Table 44. Allergan Plc Business Overview Table 45. Allergan Plc Female Infertility Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Allergan Plc Female Infertility Drugs Product Portfolio Table 47. Allergan Plc Recent Development Table 48. Ferring BV Company Information Table 49. Ferring BV Business Overview Table 50. Ferring BV Female Infertility Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Ferring BV Female Infertility Drugs Product Portfolio Table 52. Ferring BV Recent Development Table 53. Merck KGaA Company Information Table 54. Merck KGaA Business Overview Table 55. Merck KGaA Female Infertility Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Merck KGaA Female Infertility Drugs Product Portfolio Table 57. Merck KGaA Recent Development Table 58. Novartis AG Company Information Table 59. Novartis AG Business Overview Table 60. Novartis AG Female Infertility Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Novartis AG Female Infertility Drugs Product Portfolio Table 62. Novartis AG Recent Development Table 63. Sanofi Company Information Table 64. Sanofi Business Overview Table 65. Sanofi Female Infertility Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Sanofi Female Infertility Drugs Product Portfolio Table 67. Sanofi Recent Development Table 68. Research Programs/Design for This Report Table 69. Authors List of This Report Table 70. Secondary Sources Table 71. Primary Sources List of Figures Figure 1. Female Infertility Drugs Product Image Figure 2. Global Female Infertility Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Female Infertility Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Female Infertility Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Parenteral Image Figure 8. Oral Image Figure 9. Others Image Figure 10. Global Female Infertility Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Female Infertility Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Female Infertility Drugs Sales Value Share by Type (2021-2032) Figure 13. Low Birth Weight Image Figure 14. Multiple-gestation Pregnancies Image Figure 15. Multiple-birth Infants Image Figure 16. Ovarian Hyperstimulation Syndrome Image Figure 17. Risk of Cesarean Delivery Image Figure 18. Premature Labor Image Figure 19. Global Female Infertility Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Female Infertility Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Female Infertility Drugs Sales Value Share by Application (2021-2032) Figure 22. Global Female Infertility Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global Female Infertility Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America Female Infertility Drugs Sales Value (2021-2032) & (US$ Million) Figure 25. North America Female Infertility Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe Female Infertility Drugs Sales Value (2021-2032) & (US$ Million) Figure 27. Europe Female Infertility Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific Female Infertility Drugs Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific Female Infertility Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America Female Infertility Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. South America Female Infertility Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa Female Infertility Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa Female Infertility Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA Female Infertility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada Female Infertility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico Female Infertility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany Female Infertility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France Female Infertility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. Female Infertility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy Female Infertility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain Female Infertility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia Female Infertility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands Female Infertility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries Female Infertility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China Female Infertility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan Female Infertility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea Female Infertility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India Female Infertility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia Female Infertility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia Female Infertility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil Female Infertility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina Female Infertility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile Female Infertility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia Female Infertility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru Female Infertility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Female Infertility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel Female Infertility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE Female Infertility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey Female Infertility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran Female Infertility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt Female Infertility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • Parenteral
  • Oral
  • Others
Applications
  • Low Birth Weight
  • Multiple-gestation Pregnancies
  • Multiple-birth Infants
  • Ovarian Hyperstimulation Syndrome
  • Risk of Cesarean Delivery
  • Premature Labor
Companies covered
  • Allergan Plc
  • Ferring BV
  • Merck KGaA
  • Novartis AG
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Female Infertility Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Female Infertility Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Female Infertility Drugs Market Dynamics
  1. 2.1 Female Infertility Drugs Industry Trends
  2. 2.2 Female Infertility Drugs Industry Drivers
  3. 2.3 Female Infertility Drugs Industry Opportunities and Challenges
  4. 2.4 Female Infertility Drugs Industry Restraints
3 Female Infertility Drugs Market by Company
  1. 3.1 Global Female Infertility Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Female Infertility Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Female Infertility Drugs Company Ranking (2024-2026)
  4. 3.4 Global Female Infertility Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Female Infertility Drugs Company Product Type and Application
  6. 3.6 Global Female Infertility Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Female Infertility Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Female Infertility Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Female Infertility Drugs Market by Type
  1. 4.1 Female Infertility Drugs Type Introduction
  2. 4.1.1 Parenteral
  3. 4.1.2 Oral
  4. 4.1.3 Others
  5. 4.2 Global Female Infertility Drugs Sales Value by Type
  6. 4.2.1 Global Female Infertility Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Female Infertility Drugs Sales Value by Type (2021-2032)
  8. 4.2.3 Global Female Infertility Drugs Sales Value Share by Type (2021-2032)
5 Female Infertility Drugs Market by Application
  1. 5.1 Female Infertility Drugs Application Introduction
  2. 5.1.1 Low Birth Weight
  3. 5.1.2 Multiple-gestation Pregnancies
  4. 5.1.3 Multiple-birth Infants
  5. 5.1.4 Ovarian Hyperstimulation Syndrome
  6. 5.1.5 Risk of Cesarean Delivery
  7. 5.1.6 Premature Labor
  8. 5.2 Global Female Infertility Drugs Sales Value by Application
  9. 5.2.1 Global Female Infertility Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Female Infertility Drugs Sales Value by Application (2021-2032)
  11. 5.2.3 Global Female Infertility Drugs Sales Value Share by Application (2021-2032)
6 Female Infertility Drugs Regional Value Analysis
  1. 6.1 Global Female Infertility Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Female Infertility Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Female Infertility Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Female Infertility Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Female Infertility Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Female Infertility Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Female Infertility Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Female Infertility Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Female Infertility Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Female Infertility Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Female Infertility Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Female Infertility Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Female Infertility Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Female Infertility Drugs Sales Value Share by Country, 2025 VS 2032
7 Female Infertility Drugs Country-level Value Analysis
  1. 7.1 Global Female Infertility Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Female Infertility Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Female Infertility Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Female Infertility Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Female Infertility Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Female Infertility Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Female Infertility Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Female Infertility Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Female Infertility Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Female Infertility Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Female Infertility Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Female Infertility Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Female Infertility Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Female Infertility Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Female Infertility Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Female Infertility Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Female Infertility Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Female Infertility Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Female Infertility Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Female Infertility Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Female Infertility Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Female Infertility Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Female Infertility Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Female Infertility Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Female Infertility Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Female Infertility Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Female Infertility Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Female Infertility Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Female Infertility Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Female Infertility Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Female Infertility Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Female Infertility Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Female Infertility Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Female Infertility Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Allergan Plc
  2. 8.1.1 Allergan Plc Company Information
  3. 8.1.2 Allergan Plc Business Overview
  4. 8.1.3 Allergan Plc Female Infertility Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Allergan Plc Female Infertility Drugs Product Portfolio
  6. 8.1.5 Allergan Plc Recent Developments
  7. 8.2 Ferring BV
  8. 8.2.1 Ferring BV Company Information
  9. 8.2.2 Ferring BV Business Overview
  10. 8.2.3 Ferring BV Female Infertility Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Ferring BV Female Infertility Drugs Product Portfolio
  12. 8.2.5 Ferring BV Recent Developments
  13. 8.3 Merck KGaA
  14. 8.3.1 Merck KGaA Company Information
  15. 8.3.2 Merck KGaA Business Overview
  16. 8.3.3 Merck KGaA Female Infertility Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck KGaA Female Infertility Drugs Product Portfolio
  18. 8.3.5 Merck KGaA Recent Developments
  19. 8.4 Novartis AG
  20. 8.4.1 Novartis AG Company Information
  21. 8.4.2 Novartis AG Business Overview
  22. 8.4.3 Novartis AG Female Infertility Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis AG Female Infertility Drugs Product Portfolio
  24. 8.4.5 Novartis AG Recent Developments
  25. 8.5 Sanofi
  26. 8.5.1 Sanofi Company Information
  27. 8.5.2 Sanofi Business Overview
  28. 8.5.3 Sanofi Female Infertility Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sanofi Female Infertility Drugs Product Portfolio
  30. 8.5.5 Sanofi Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst